Skip to main page content
Inflammation was characterized as a localized process over a century ago. Still, as McGeer and McGeer demonstrate, local inflammatory reactions remain decisive factors in some of the most important diseases of our time.
Predicted to become among the greatest pharmaceutical blockbusters, two so-called coxibs are now widely prescribed. Mardini and FitzGerald discuss the clinical ramifications of the widespread use of these drugs.
New technologies in chemistry and genomics have renewed the therapeutic appeal of “molecular” biology. Juliano et al. consider the novel macromolecular strategies within a pharmacological context.
In the pregenomics era, the molecular basis of cystic fibrosis was a revolutionary discovery. Today, as Pollard et al. show, pharmacogenomics promises to bring genome-wide perspectives to many diseases, including cystic fibrosis.
Find articles in this issue containing these words:
